Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 12/20 | 0.70 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4265827 | 0.91 | CNR1 (0.68) | CNR1PTGDR2OPRK1KMT2A | |
| SCHEMBL4272064 | 0.88 | CNR1 (0.70) | CNR1OPRK1OPRD1 | |
| SCHEMBL4274778 | 0.87 | CNR1 (0.67) | CNR1KMT2A | |
| SCHEMBL4389501 | 0.85 | CNR1 (0.73) | CNR1PTGDR2OPRK1 | |
| SCHEMBL4266867 | 0.82 | CNR1 (0.70) | CNR1OPRK1 | |
| SCHEMBL4265972 | 0.82 | CNR1 (1.00) | CNR1 | |
| SCHEMBL4275511 | 0.80 | CNR1 (0.70) | CNR1 | |
| SCHEMBL4271444 | 0.74 | CNR1 (1.00) | CNR1 | |
| SCHEMBL1946390 | 0.73 | ALDH1A1 (0.42) | CNR1PTGDR2KMT2A | |
| SCHEMBL4265815 | 0.72 | CNR1 (1.00) | CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090247499-A1 | SULFONYLATED PIPERAZINES AS CANNABINOID-1 RECEPTOR MODULATORS | MERCK SHARP & DOHME CORP. | 2009-10-01 | — | — | US | claimed |
| EP-2056828-A2 | SULFONYLATED PIPERAZINES AS CANNABINOID-1 RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2009-05-13 | — | — | EP | claimed |
| WO-2008024284-A2 | SULFONYLATED PIPERAZINES AS CANNABINOID-1 RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2008-02-28 | — | — | WO | claimed |
| EP-2056828-A2 | SULFONYLATED PIPERAZINES AS CANNABINOID-1 RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2009-05-13 | — | — | EP | disclosed |
| WO-2008024284-A2 | SULFONYLATED PIPERAZINES AS CANNABINOID-1 RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247499-A1 | SULFONYLATED PIPERAZINES AS CANNABINOID-1 RECEPTOR MODULATORS | CNR1, CNR2, FAAH | CNR1 1/4885PTGDR2 684/4885OPRK1 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.